GlassScriptPhysician profile
Alexander Rodriguez
NPI 1548480825
$1,419.81
in general payments reported to CMS, 2019-2025
21 companies · $504 in 2025
The $504 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.76 · 2020: $24.85 · 2021: $322 · 2022: $156 · 2023: $101 · 2024: $299 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $206.87 | 2020-2021 | |
| Novo Nordisk INC | $182.33 | 2023-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $156.47 | 2022 | |
| Glaxosmithkline, LLC. | $153.48 | 2019-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $133.31 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $85.12 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.34 | 2023-2025 | Jardiance |
| Amgen INC. | $61.50 | 2024-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.95 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $44.56 | 2024-2025 | Airsupra |
| Pfizer INC. | $37.99 | 2023 | |
| Hologic Sales and Service, LLC | $33.94 | 2025 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $33.68 | 2025 | Cologuard Collection Kit |
| Atricure, INC. | $26.12 | 2024 | |
| Phathom Pharmaceuticals, INC. | $24.86 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.26 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $18.90 | 2025 | Rexulti |
| Abbvie INC. | $17.66 | 2024 | |
| Eisai INC. | $15.08 | 2021 | |
| Esperion Therapeutics, INC. | $14.60 | 2025 | Nexletol |
| Shield Therapeutics INC | $13.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.